Yes, Ambien (zolpidem) is still prescribed and remains FDA-approved for the treatment of insomnia. However, prescribing patterns have shifted meaningfully over the past decade. Doctors now start with lower doses than they once did, favor non-drug therapy as a first-line treatment, and increasingly turn to newer sleep medications that carry fewer safety concerns.
Why Prescribing Has Changed
Zolpidem use has decreased somewhat in recent years, though it hasn’t disappeared. Several factors explain the shift. In 2013, the FDA required manufacturers to cut the recommended starting dose for women in half, from 10 mg to 5 mg for immediate-release tablets and from 12.5 mg to 6.25 mg for extended-release versions. The reason: women clear the drug from their bodies more slowly than men, leaving enough of it in the bloodstream the next morning to impair driving and concentration. Men were also encouraged to consider the lower dose, though it wasn’t mandated.
Then in 2019, the FDA added its most serious warning, a boxed warning, to Ambien and related sleep medications. The agency flagged rare but serious injuries and deaths caused by complex sleep behaviors, including sleepwalking, sleep driving, and performing other activities while not fully awake. These behaviors were found to be more common with zolpidem, eszopiclone, and zaleplon than with other prescription sleep aids. Under the updated guidance, doctors should not prescribe zolpidem to anyone who has previously experienced an episode of complex sleep behavior on any of these medications.
Where Ambien Fits in Treatment Today
The American Academy of Sleep Medicine positions all sleep medications, including zolpidem, as secondary options rather than first choices. The recommended starting point for chronic insomnia is cognitive behavioral therapy for insomnia (CBT-I), a structured program that addresses the thought patterns and habits that keep people awake. Medications are considered mainly for people who can’t participate in CBT-I, who still have symptoms after completing it, or who need temporary help while therapy takes effect.
Notably, the AASM’s guideline doesn’t rank one sleep medication above another because so few head-to-head comparison studies exist. Each drug recommendation, including zolpidem’s, carries a “weak” strength rating, reflecting limited certainty about which agent works best for a given patient. In practice, this means your doctor may still prescribe zolpidem if it’s a reasonable fit for your situation, but the decision is more individualized and cautious than it was a decade ago.
Who Should Not Take It
The clearest group flagged against zolpidem use is adults over 65. The American Geriatrics Society’s Beers Criteria, a widely used safety reference for prescribing to older adults, lists zolpidem under a strong “avoid” recommendation with moderate-quality evidence. The rationale: in older adults, zolpidem carries risks similar to those of benzodiazepines, including delirium, falls, fractures, increased emergency room visits, hospitalizations, and motor vehicle crashes. Meanwhile, the actual sleep benefit is modest, with only minimal improvements in how quickly people fall asleep and how long they stay asleep.
The warnings are even more specific for older adults with certain conditions. Those with delirium or a high risk of delirium should avoid zolpidem because it can trigger or worsen episodes. People with dementia or cognitive impairment face additional central nervous system side effects. And for anyone with a history of falls or fractures, the drug should be avoided unless safer alternatives aren’t available.
Next-Morning Impairment
One of the most practical concerns with zolpidem is how long it affects you after you wake up. The drug is designed to knock you out quickly, but its effects don’t always wear off by morning. Performance problems can persist into the next day, particularly at higher doses or in people who metabolize the drug slowly. The manufacturer’s own labeling warns against driving after taking the drug, and research supports the conclusion that even normal therapeutic doses can impair driving ability for several hours after use.
This next-morning grogginess was the core reason behind the FDA’s 2013 dose reduction. Blood levels of zolpidem measured the morning after a nighttime dose were high enough in many women to affect coordination and reaction time during the morning commute. The lower doses were specifically calibrated to reduce that risk.
Newer Alternatives Gaining Ground
Part of the reason zolpidem prescriptions have declined is the arrival of a newer class of sleep medications called dual orexin receptor antagonists, or DORAs. These drugs work differently from zolpidem. Instead of broadly sedating the brain, they block a specific chemical signaling system that keeps you awake, promoting sleep through a more targeted mechanism.
Three DORAs are currently available: suvorexant, lemborexant, and daridorexant. In a systematic review comparing 20 insomnia medications, DORAs scored highest for the measures that matter most to patients: how quickly you fall asleep, how much time you spend awake after initially dozing off, total sleep time, and overall sleep efficiency. They also had the second-best safety profile, behind only placebo.
DORAs carry a lower risk of abuse and physical dependence based on post-marketing surveillance data. They also appear safer for populations that struggle most with zolpidem. Suvorexant, for example, has been approved for sleep problems in people with mild to moderate Alzheimer’s disease. In studies, it didn’t impair next-morning cognitive or motor performance and didn’t worsen the underlying cognitive decline. That profile stands in contrast to zolpidem, which is explicitly flagged as harmful in patients with dementia.
What This Means If You’re Currently Taking It
If you already have a zolpidem prescription that works for you without side effects, there’s no blanket reason to stop. The drug remains approved and available in both brand-name and generic forms. But if you’re experiencing next-morning grogginess, you’re over 65, or you’ve ever had a sleepwalking or sleep-driving episode, those are concrete reasons to talk with your prescriber about whether a different approach makes more sense.
For people newly seeking help with insomnia, the landscape looks different than it did ten years ago. Behavioral therapy is the preferred starting point, and when medication is needed, doctors now have alternatives that weren’t available when Ambien dominated the market. Zolpidem still has a role, but it’s a narrower one, reserved for specific situations rather than used as a default.